Inhibrx Biosciences, Inc.
INBX • NASDAQ
Inhibrx Biosciences, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Mark Paul Lappe, with a market cap of $852.9M.
CEOMark Paul Lappe
Next Earnings
Upcoming earnings announcement for Inhibrx Biosciences, Inc.
Date
Wednesday, May 13, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.55
Earnings History
Past 12 earnings reports for Inhibrx Biosciences, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 19, 2026 | Q4 2025 | -$2.11Est: -$2.45 | +13.9% | - | — |  10-K |
| Nov 14, 2025 | Q3 2025 | -$2.28Est: -$2.21 | -3.2% | - | — | 10-Q |
| Aug 13, 2025 | Q2 2025 | -$1.85Est: -$2.73 | +32.2% | $1.3M | — | 10-Q |
| May 14, 2025 | Q1 2025 | -$2.80Est: -$3.45 | +18.8% | - | — | 10-Q |
| Mar 17, 2025 | Q4 2024 | -$3.09 | — | $100.0K | — | 10-K |
| Nov 14, 2024 | Q3 2024 | -$2.84Est: -$3.38 | +16.0% | - | — | 10-Q |
| Aug 13, 2024 | Q2 2024 | $125.48Est: -$1.47 | +8636.1% | $100.0K | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$1.44Est: -$1.51 | +4.6% | - | — | — |
| Feb 28, 2024 | Q4 2023 | -$1.73Est: -$1.04 | -66.3% | $1.6MEst: $50.0K | +3168.0% | — |
| Nov 9, 2023 | Q3 2023 | -$1.10Est: -$1.01 | -8.9% | $119.0K | — | — |
| Aug 7, 2023 | Q2 2023 | -$1.08Est: -$1.03 | -4.9% | $30.0K | — | — |
| May 8, 2023 | Q1 2023 | -$1.12Est: -$0.84 | -33.3% | $17.0KEst: $150.0K | -88.7% | — |